Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.49 |
| ▸ | MAPT | P10636 | 7/20 | 0.49 |
| ▸ | RAB9A | P51151 | 5/20 | 0.49 |
| ▸ | NPC1 | O15118 | 4/20 | 0.49 |
| ▸ | LMNA | P02545 | 4/20 | 0.49 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.45 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.40 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.40 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4824879 | 1.00 | MEN1 (0.49) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL4822814 | 0.85 | MAPT (0.50) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL1753018 | 0.77 | MEN1 (0.51) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL4828305 | 0.77 | MEN1 (0.59) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL4825016 | 0.77 | KMT2A (0.83) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL15540046 | 0.76 | RAB9A (0.45) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL1463431 | 0.70 | NPC1 (0.49) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL20180830 | 0.70 | NPC1 (0.48) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL20167669 | 0.70 | NPC1 (0.48) | MEN1KMT2AMAPTRAB9ANPC1 | |
| SCHEMBL16919552 | 0.69 | HTT (0.47) | MEN1KMT2AMAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7400979-B2 | Kinase inhibitors; genetic engineering | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | disclosed |
| US-7332497-B2 | As inhibitors of protein kinases | ABBOTT GMBH & CO KG (DE) | 2008-02-19 | — | — | US | disclosed |
| US-6921763-B2 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2005-07-26 | — | — | US | disclosed |
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2004-01-08 | — | — | US | disclosed |
| US-20030175935-A1 | Method of identifying inhibitors of Lck | ABBVIE INC. | 2003-09-18 | — | — | US | disclosed |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | ABBOTT LABORATORIES (US) | 2002-10-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040006083-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, UGT1A1, ABCB1 | MEN1 2926/4885KMT2A 3130/4885MAPT 3448/4885 |
| US-20030175935-A1 | Method of identifying inhibitors of Lck | LCK, FYN, ZAP70 | MEN1 4263/4885KMT2A 2625/4885MAPT 2765/4885 |
| US-20020156081-A1 | Pyrazolopyrimidines as therapeutic agents | DPYD, CYP2D6, UGT1A1 | MEN1 2274/4885KMT2A 3670/4885MAPT 3263/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.